drugset / Trial / NCT06440252

Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults

NCT06440252

Phase 3 Completed 35 enrolled RDC Clinical Pty Ltd
RandomizedCrossoverDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, 2 arm crossover study conducted over 11 weeks, with participants randomised to a product for 4 weeks, followed by a 3-week washout period before completing the second product for 4 weeks, to study the effectiveness of a grape seed extract on circulatory measures in healthy adults.

Timeline

Start
2024-10-31
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Grape Seed Extract Unknown 600 mg

Indications

No indication recorded.